SLE linked to subsequent risk of malignant melanoma

PORTLAND, ORE. – A diagnosis of systemic lupus erythematosus (SLE) significantly increases the risk of a subsequent diagnosis of malignant melanoma, according to the results of a large, first-in-kind, single-center longitudinal analysis of electronic medical records.

Treatment of Malignant Melanoma

Patients who have recurrent metastatic disease, stage 4 disease, the median life expectancy is now actually an unknown.

Preliminary Workup for Signs of Recurrent Melanoma

This is a 46-year-old woman who was diagnosed with a stage 3C melanoma now about a year ago, initially with a deep ulcerated primary tumor and multiple involved lymph nodes.

Treatment of Metastatic Melanoma Beyond Progression

For a patient who has BRAF-mutant melanoma, there really is no wrong initial answer in terms of what to try.

Cancer in the News

Feature Articles

Study points to melanoma breakthrough

Advanced melanoma patients with brain tumours may be able to live longer using a combination of immunotherapy drugs, an Australian trial has shown.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Where you live could affect your risk of skin cancer: StatsCan

Statistics Canada and the Canadian Cancer Society are urging Canadians to be aware of the UV index as they head out for the long weekend.

Read the full story

Posted in Melanoma In The News

Data for KEYTRUDA® (pembrolizumab) Across 16 Types of Cancer from Merck’s Industry-Leading Immuno-Oncology Program to Be Presented at the 2017 ASCO Annual Meeting

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new and updated data from studies of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, will be presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 2 – 6, 2017.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Syndax Announces Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Melanoma

WALTHAM, Mass., May 17, 2017 (GLOBE NEWSWIRE) — Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced results from the melanoma cohort of the ongoing Phase 2 ENCORE 601 trial of entinostat in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 (programmed […]

Read the full story

Posted in Melanoma In The News, Clinical Trials

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories